期刊文献+

来曲唑合成工艺改进

Improvement on Synthesis of Letrozole
下载PDF
导出
摘要 以对氯苯腈等物为原料,进行的各种取代反应合成实验实行改进,考察了每一反应步骤中反应温度对反应进程的影响并对反应曲线进行了解释。实验结果表明,最佳的反应温度为:合成化合物1的较佳反应温度为60℃;生成化合物2的最佳置换反应温度为55℃。第三步取代反应将反应温度用冰水浴控制在0℃。改进后的实验廉价、易操作、产率高,对工业生产及实验教学有积极的指导作用。 A promoted route to synthesizing letrozole was introduced. Using chlorobenzonitrile as reactants, the preparation of letrozole acetate was improved. The factors which influence the reactive performance of letrozole acetate were investigated and optimized, including reaction temperature of each step. The results indicate that the best reaction conditions are as follows: The temperature is 60 ~C , when synthesizing compound 1, the temperature is 55 ~C , when synthesizing compound 2, and the temperature should be controlled to 0 ~C by ice-water system, when synthesizing compound 3. The improved experiment is cheap, easy to operate, and productive. It has instructional significance for industrial production and experimental teaching.
作者 夏凡
出处 《实验室研究与探索》 CAS 北大核心 2012年第8期216-218,共3页 Research and Exploration In Laboratory
关键词 来曲唑 合成化合物 取代反应 最佳反应温度 letrozole synthetic compounds substitution reaction optimum reaction temperature
  • 相关文献

参考文献16

  • 1Buzdar A, Jonat W, Howwell A, et al. Anastrozole versusmegest rol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phaseⅢ trials [ J]. Cancer, 1998 (83) :1142-1152.
  • 2Kaufmann M,Bajetta E, Dirix L Y,et al. Exemestane is superior to megestrol acetate after tamoxifen failure in post menopausal women with advanced breast cancer; result s of a phase Ⅲ randomised double-blind study [ J ]. Clin Oncol,2000 ( 18 ) : 1399 -1411.
  • 3Dombemowsky P, Smith I E, Falkson G, et al. Let -rozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randonfised trial showing a dose-effect and improved efficacy and tolerability compared with megestrol acetate [ J ]. Clin Oncol, 1998 (16) :453 -461.
  • 4Gershanovich M,Chaudri H A, Campos D, et al. Let rozole, a new oral aromtase inhibitor : randomised trial comparing 2.5 mg daily, 0. 5 mg daily and aminoglutethimide in post menopausal women with advanced breast cancer[J]. Ann On ologv, 1998 (9) :639 -645.
  • 5Nabhohz J M, Buzdar A, Pollak M, et al. , Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer inpostmenopansal women: results of a North American multicentrerandomised trial [ J]. Clin Oncol, 2000( 18 ) :3758-3767.
  • 6Bonneterre J, Thurlimann B, Robert son J F R, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomised group efficacy and tolerability study [ J]. Clin Oncol, 2001(18) :3748 -3757.
  • 7Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of Letrozole (Femara) versus tamoxifen as first-linet -herapy for postmenopausal women with advanced breast cancer: results of a phase m study of the International Letrozole Breast Cancer Group[J].Clin 0neol,2001 ( 19 ) :2596 -2606.
  • 8Bhatnagar A S. Aromatase inhibitors[J].J Steroid Biochem MolecBio, 1990,37 ( 6 ) : 1021-1027.
  • 9杨洁,韩为东,赵亚力.雌激素与乳腺癌[J].现代肿瘤医学,2007,15(3):431-433. 被引量:22
  • 10方仁杏,陈振东.来曲唑治疗绝经后乳腺癌的进展[J].实用癌症杂志,2008,23(1):100-101. 被引量:6

二级参考文献79

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部